High bacteria levels detected at local beach
Read only: Man sentenced to prison for threatening police officer
The beach at Mosquito Lake State Park was found to have high bacteria levels, according to an alert issued Thursday afternoon.
The last time high E. coli levels were detected at that beach was last August.
The latest advisory will remain posted until a follow-up sample is below the recreational standard. The state's website will have any updates.
Children, the elderly, and those in ill health or weakened immune systems are advised not to swim.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Over 100 people being investigated for vape offences, say MOH and HSA
SINGAPORE – More than 100 people are under investigation for offences involving vapes, said the Ministry of Health (MOH) and the Health Sciences Authority (HSA) on Aug 14. In a joint statement, MOH and HSA said 18 individuals are facing charges in court for offences under the Tobacco (Control of Advertisements and Sale) Act involving the sale, advertising or import of e-vaporisers. As at Aug 14, five people have been charged over the sale or importation of etomidate-laced e-vaporisers. HSA is also investigating about 65 cases involving the possession, sale or importation of etomidate-laced e-vaporisers. Another 100 are under investigation for offences involving non-etomidate e-vaporisers under the Tobacco (Control of Advertisements and Sale) Act, said the authorities. They said: 'MOH and HSA have been intensifying enforcement actions against etomidate-laced e-vaporiser offences in Singapore.' Under the Poisons Act, those convicted of possessing, importing or selling pods containing etomidate can be jailed for up to two years and/or fined up to $10,000. MOH and HSA said etomidate will soon be classified as a Class C controlled drug under the Misuse of Drugs Act. Offenders caught using etomidate-laced e-vaporisers will be subject to mandatory supervision and rehabilitation. Repeat offenders are liable to be prosecuted and subject to jail for at least a year. More severe penalties apply to those selling, distributing or importing these devices, including imprisonment of up to 20 years and caning. 'Users of e-vaporisers, particularly those consuming etomidate, are strongly urged to cease consumption immediately,' said MOH and HSA. The increase in enforcement numbers comes after The Straits Times launched its anti-vaping campaign called Vaping: The Invisible Crisis on July 13. Etomidate is meant for use only during medical procedures. When vaped, etomidate enters the lungs directly, potentially triggering spasms, breathing difficulties, seizures and even psychosis. If etomidate is listed as a Class C drug, abusers can be subjected to supervision and mandatory participation in a rehabilitation programme or committed to drug rehabilitation centres, similar to what drug abusers undergo. Under current laws, possessing, using or buying vapes carries a maximum fine of $2,000. Those found in possession of or using pods containing etomidate can be jailed for up to two years and fined up to $10,000. The measures listed in the MOH-HSA joint statement are among the latest the authorities have taken to tackle the vape scourge in Singapore. On Aug 13, HSA said it was working with Hong Kong's Department of Health (DOH) to tackle vaping by exchanging information and expertise with each other. HSA signed a memorandum of understanding with the DOH for cooperation in healthcare regulatory matters involving health products. Also on Aug 13, ST reported HSA had recently advertised job openings for investigators specifically to crack down on Kpods. As at Aug 14, more than 500 people have applied for the job. The public can report vaping offences to the Tobacco Regulation Branch on 6684-2036 or 6684-2037 from 9am to 9pm daily, or online at Those who need help to quit vaping can join the Health Promotion Board's I Quit programme by calling the QuitLine on 1800-438-2000. The authorities have said those who voluntarily seek support to quit vaping will not face any penalties for doing so. Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here
Business Upturn
17 hours ago
- Business Upturn
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Wire
20 hours ago
- Business Wire
Together Women's Health Named to Inc. 5000 List for Third Consecutive Year
DETROIT--(BUSINESS WIRE)--Together Women's Health (TWH) proudly announces its inclusion on the 2025 Inc. 5000 list for the third year in a row. This honor places Together Women's Health among the most dynamic businesses in America across all industries. Together Women's Health is a women's health-focused management service organization, committed to partnering with leading physicians to build a premier network of women's health services in the U.S. TWH's affiliate network consists of 20 practices with nearly 200 providers delivering women's health services at 57 locations throughout Michigan, Illinois, Alabama, Colorado, Mississippi, Missouri, Georgia, Tennessee and Kentucky. Being named to the Inc. 5000 list for the third year in a row is a tremendous honor and a testament to the extraordinary network of women's healthcare providers who serve patients with excellence every day across the country Share The Inc. 5000 ranking celebrates companies that have achieved rapid revenue growth while demonstrating resilience, innovation, and leadership in their fields. Together Women's Health's recognition highlights the organization's commitment to advancing women's healthcare through strategic partnerships with top physicians, investment in clinical and operational excellence, and a patient-first approach to care. 'Being named to the Inc. 5000 list for the third year in a row is a tremendous honor and a testament to the extraordinary network of women's healthcare providers who serve patients with excellence every day across the country,' said Anthony Ahee, Founder and CEO of Together Women's Health. 'This recognition also reflects the dedication of our incredible team, whose passion for elevating and innovating women's health is making a real difference in the lives of the patients and communities we serve.' Together Women's Health is a growing network of leading women's healthcare practices committed to delivering exceptional, individualized care for women at every stage of life. The organization partners with leading physicians to build a premier network of women's health services in the U.S.—from routine gynecologic and obstetric care, breast health, advanced gynecologic procedures, menopause management, urogynecology, maternal fetal medicine, and more. With a focus on clinical and operational excellence, innovation, and compassionate care, Together Women's Health empowers providers to thrive while elevating the patient experience. The recognition on the 2025 Inc. 5000 list follows a year of significant milestones, including expanding into new states, adding maternal-fetal medicine expertise, and opening an Imaging Center dedicated to breast health. To learn more about a partnership with Together Women's Health, visit or contact us at partner@ About Together Women's Health Headquartered in Detroit, MI, Together Women's Health ('TWH') is a women's health management services organization committed to partnering with leading physicians to build a premier network of obstetricians and gynecologists. TWH, recently named on the Inc. 5000 list of fastest growing companies in America, supports its affiliated practices and physician partners throughout multiple states with strategic guidance, administrative resources (including revenue cycle management, marketing, human resources, finance, accounting, and IT), operational expertise and capital, thereby allowing physicians to focus on clinical excellence and serving their communities. TWH is building a network of top clinicians in a physician-led culture. For more information about Together Women's Health, please visit About Shore Capital Partners Shore Capital, a Chicago-based private equity firm with offices in Nashville, is an investor in lower middle market companies in the Healthcare, Food and Beverage, Business Services, Industrial, and Real Estate industries. Shore's strategy is to support management partners to grow faster with less risk through access to capital, world-class board and operational resources, and unmatched networking, development, and shared learnings across the portfolio. From 2020-2024, Shore received recognition from Inc Magazine as a 5x Top Founder Friendly Investor and by Pitchbook Research for leading U.S. Private Equity deal volume for the past 10 years, from 2015-2024. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant potential to grow through industry consolidation and organic growth to generate value for shareholders. Shore has approximately $13 billion of assets under management and in additional investment platforms to which it provides business and operational consulting services. To learn more about Shore Capital Partners, please visit
